We develop next-generation microbiome-derived products to advance human health.
More information
Manufactured to international quality and safety standards
Compliant with globally recognized quality management standards
Ensures food safety through hazard control standards
Distributed in 14 markets across Europe & Asia
The next generation of medicine will not come from inventing molecules, but from listening to the ones that already live inside us.
Medalta is a microbiome science company developing scientifically-grounded, microbiome-derived products for everyday wellness and chronic conditions.
We work with characterised strains, clinically-studied actives and a formulation discipline borrowed from pharmaceuticals — not from supplements.
Each line addresses a different need
— but every formula traces back to the same library of characterised strains.
Everyday microbiome support for adults and kids. Living strains, simple regimens, designed to be the easiest pill of your day.
Explore line
Higher-strength formulations for specific conditions — gastric, urinary, inflammatory. Co-developed with clinicians.
Explore line
Our flagship anti-inflammatory programme. Postbiotic-derived, omega-stabilised, mechanism-led.
Explore line
Each line addresses a different need
— but every formula traces back to the same library of characterised strains.
Our flagship anti-inflammatory programme. Postbiotic-derived, omega-stabilised, mechanism-led.
Our flagship anti-inflammatory programme. Postbiotic-derived, omega-stabilised, mechanism-led.
Our flagship anti-inflammatory programme. Postbiotic-derived, omega-stabilised, mechanism-led.
A cross-section of where our work stands today. Living data — updated as new trials, strains and markets come online.
120+
Characterised bacterial strains in our reference library
9
Clinical or pre-clinical studies in active programmes
3.2M
Daily doses produced under GMP per year
14
International markets where Medalta is distributed
Medalta partners with distributors, clinics and brands on white-label microbiome lines, regional registration and clinical co-development.
